Computational biologist/bioinformatician - (Cambridge, MA)

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce 1st focuses on specific cell types within the human tumor microenvironment (TME) to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce has 3 development stage programs: its 2 clinical product candidates, JTX-2011, a monoclonal antibody that binds to and activates ICOS, and JTX-4014, a monoclonal antibody that binds to PD-1 to be used in combination with its pipeline of future product candidates, and JTX-8064, a monoclonal antibody that binds to Leukocyte Immunoglobulin Like Receptor B2 (LILRB2) that is currently in the IND-enabling phase. For more info, please visit www.jouncetx.com.